Beryl Drugs 過去の業績
過去 基準チェック /26
Beryl Drugs has been growing earnings at an average annual rate of 20.2%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 21.4% per year. Beryl Drugs's return on equity is 6.8%, and it has net margins of 2.4%.
主要情報
20.2%
収益成長率
20.2%
EPS成長率
Pharmaceuticals 業界の成長 | 17.5% |
収益成長率 | 21.4% |
株主資本利益率 | 6.8% |
ネット・マージン | 2.4% |
前回の決算情報 | 30 Jun 2024 |
最近の業績更新
Recent updates
収支内訳
Beryl Drugs の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Jun 24 | 249 | 6 | 20 | 0 |
31 Mar 24 | 267 | 8 | 20 | 0 |
31 Dec 23 | 299 | 12 | 19 | 0 |
30 Sep 23 | 304 | 10 | 19 | 0 |
30 Jun 23 | 301 | 11 | 18 | 0 |
31 Mar 23 | 269 | 8 | 17 | 0 |
31 Dec 22 | 242 | 2 | 15 | 0 |
30 Sep 22 | 193 | 0 | 15 | 0 |
30 Jun 22 | 149 | -8 | 13 | 0 |
31 Mar 22 | 146 | -7 | 13 | 0 |
31 Dec 21 | 172 | -1 | 14 | 0 |
30 Sep 21 | 161 | -1 | 13 | 0 |
30 Jun 21 | 160 | 8 | 12 | 0 |
31 Mar 21 | 141 | 2 | 12 | 0 |
31 Dec 20 | 111 | -4 | 11 | 0 |
30 Sep 20 | 113 | -2 | 11 | 0 |
30 Jun 20 | 113 | -5 | 10 | 0 |
31 Mar 20 | 128 | 0 | 10 | 0 |
31 Dec 19 | 120 | 7 | 9 | 0 |
30 Sep 19 | 128 | 8 | 9 | 0 |
30 Jun 19 | 130 | 7 | 9 | 0 |
31 Mar 19 | 130 | 6 | 9 | 0 |
31 Dec 18 | 143 | 8 | 9 | 0 |
30 Sep 18 | 148 | 7 | 9 | 0 |
30 Jun 18 | 145 | 11 | 8 | 0 |
31 Mar 18 | 152 | 10 | 8 | 0 |
31 Dec 17 | 141 | 7 | 7 | 0 |
30 Sep 17 | 130 | 5 | 8 | 0 |
30 Jun 17 | 128 | 1 | 9 | 0 |
31 Mar 17 | 113 | -4 | 10 | 0 |
31 Dec 16 | 102 | 0 | 11 | 0 |
30 Sep 16 | 105 | 1 | 12 | 0 |
30 Jun 16 | 115 | 2 | 13 | 0 |
31 Mar 16 | 131 | 2 | 12 | 0 |
31 Dec 15 | 150 | 1 | 14 | 0 |
30 Sep 15 | 150 | 1 | 22 | 0 |
30 Jun 15 | 146 | 3 | 40 | 0 |
31 Mar 15 | 133 | 1 | 12 | 0 |
31 Dec 14 | 121 | 1 | 24 | 0 |
30 Sep 14 | 130 | 2 | 22 | 0 |
30 Jun 14 | 137 | 2 | 22 | 0 |
31 Mar 14 | 146 | 3 | 21 | 0 |
31 Dec 13 | 135 | 2 | 17 | 0 |
質の高い収益: 524606 has high quality earnings.
利益率の向上: 524606's current net profit margins (2.4%) are lower than last year (3.6%).
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: 524606's earnings have grown significantly by 20.2% per year over the past 5 years.
成長の加速: 524606's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
収益対業界: 524606 had negative earnings growth (-43.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (19.1%).
株主資本利益率
高いROE: 524606's Return on Equity (6.8%) is considered low.